Welcome to our dedicated page for Incannex Healthcare news (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Ltd (IXHL) is a clinical-stage biopharmaceutical innovator developing novel cannabinoid and psychedelic-assisted therapies for chronic medical conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's research advancements and operational milestones.
Access authoritative information about IXHL's clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes press releases on sleep apnea therapies, inflammatory disease treatments, and neurological disorder research – all critical to understanding the company's progress in psychedelic medicine and cannabinoid science.
Key updates cover therapeutic program developments, Australian medicinal cannabis license utilization, and financial strategy implementations. Stay informed about IXHL's pioneering work through verified announcements regarding clinical-stage breakthroughs and research collaborations.
Bookmark this page for direct access to Incannex Healthcare's official communications. Regularly updated content ensures you maintain current awareness of their innovative approaches to addressing unmet medical needs through advanced pharmaceutical research.
Incannex Healthcare Limited (Nasdaq: IXHL) has appointed Mr. Robert B. Clark to its Board of Directors, effective August 17, 2022. With over 38 years of regulatory experience, including significant roles at Pfizer and Novo Nordisk, Clark's leadership in securing FDA approvals for twelve new drugs is notable. His expertise in FDA interactions and regulatory strategies will bolster Incannex's mission in cannabinoid and psychedelic therapies, which are vital for unmet medical needs. This addition aims to enhance the company's regulatory strategy and strengthen its development initiatives.
Incannex Healthcare Limited (IXHL) has partnered with Curia to scale up the cGMP manufacturing of IHL-216A, a drug aimed at treating concussion and traumatic brain injury (TBI). This follows a successful proof-of-concept formulation development. A patent has been filed for IHL-216A, which has demonstrated superior neuroprotective effects compared to CBD in preclinical studies. The first batch from Curia will be utilized in a Phase 1 clinical trial, with an FDA pre-IND meeting targeted for Q3 2022 to discuss further development.
Incannex Healthcare Limited (NASDAQ: IXHL) announced its quarterly activities report for the period ending June 30, 2022. The company reported positive phase 2a clinical trial results for its cannabinoid drug IHL-42X, achieving a 50.7% reduction in the apnoea hypopnea index among participants with obstructive sleep apnoea. Pre-clinical studies on its neuroprotective drug IHL-216A also showed promising results in treating concussion-related injuries. Additionally, Incannex acquired APIRx Pharmaceuticals, expanding its portfolio of therapeutic candidates aimed at various conditions. The company ended the quarter with A$37.5M in cash.
Incannex Healthcare Limited (NASDAQ: IXHL) has announced the approval of a phase 1 clinical trial for its cannabinoid drug IHL-675A by the Bellberry Human Research Ethics Committee. The trial aims to assess the drug's safety and pharmacokinetics at CMAX Clinical Research in Adelaide, Australia, with patient recruitment set to begin in August 2022. IHL-675A combines cannabidiol (CBD) and hydroxychloroquine (HCQ), showing better anti-inflammatory potential in preclinical studies. Successful trial outcomes will support regulatory submissions for conditions like rheumatoid arthritis, inflammatory bowel disease, and lung inflammation.
Incannex Healthcare Limited (NASDAQ: IXHL) has announced promising results from its Phase 2 clinical trial for IHL-42X aimed at treating obstructive sleep apnoea (OSA). The study revealed that low-dose IHL-42X achieved an average reduction of 50.7% in the apnoea hypopnoea index (AHI), surpassing individual component medications. The low dose also significantly reduced the oxygen desaturation index by 59.7%, suggesting enhanced sleep quality. Importantly, low-dose IHL-42X was well tolerated with fewer treatment-emergent adverse events compared to placebo, indicating a favorable safety profile.
Incannex Healthcare Limited (NASDAQ: IXHL) has successfully completed a pre-IND meeting with the FDA regarding its drug IHL-42X, aimed at treating obstructive sleep apnoea (OSA). The FDA expressed constructive feedback and supported the proposed development program, allowing the company to bypass animal studies. This marks a significant advancement toward opening an IND application and conducting clinical trials in the U.S. Preliminary results from a phase 2 trial showed 60% of participants had over 55% AHI reduction. A complete report is expected in June 2022.
Incannex Healthcare Limited (Nasdaq: IXHL) has entered a Share Sale and Purchase Agreement to acquire 100% of APIRx Pharmaceuticals USA, LLC. The acquisition involves issuing 218,169,506 new shares valued at $0.573 each. Subject to shareholder approval and customary conditions, completion is anticipated in June 2022. The Sellers provide warranties and indemnities typical for such transactions. CEO Joel Latham expressed confidence in the acquisition, highlighting significant growth opportunities and a robust cash position to pursue diverse product developments.
Incannex Healthcare Limited (Nasdaq: IXHL) announced positive results for its drug IHL-216A, demonstrating a strong neuroprotective effect in a rodent model of sports concussion. In studies conducted with the NFL, IHL-216A notably restored spatial memory within 24 hours post-injury, outperforming both CBD and isoflurane treatments. The company plans to meet with the FDA in Q3 2022 to discuss expedited clinical trials for IHL-216A's potential application in treating traumatic brain injuries. This development follows earlier successful animal studies conducted in 2020.
Incannex Healthcare Limited (IXHL) reported promising phase 2a clinical trial results for IHL-42X, with 60% of participants showing over a 55% reduction in Apnoea Hypopnea Index (AHI), and 20% achieving reductions exceeding 80%. The company is advancing several initiatives, including a second clinical psychedelic therapy program and an acquisition of APIRx Pharmaceuticals for US$93.3M, which supports 22 cannabinoid R&D projects. With cash reserves of A$40.0M, Incannex aims to enhance its product pipeline in cannabinoid and psychedelic medicine.
On April 28, 2022, Incannex Healthcare Limited (Nasdaq: IXHL) announced the completion of its loyalty option offer, successfully raising A$23.6M. The options expired on April 22, allowing for the issuance of 67.3M new shares; for every two new shares, one piggy-back option will be granted with an exercise price of A$1.00. The additional funding will support clinical research and development activities ramping up in 2022 and 2023. Incannex's directors allocated their shares of approximately A$4.1M to a strategic investor group to enhance liquidity on NASDAQ.
